0001567619-22-000817.txt : 20220106
0001567619-22-000817.hdr.sgml : 20220106
20220106185529
ACCESSION NUMBER: 0001567619-22-000817
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220104
FILED AS OF DATE: 20220106
DATE AS OF CHANGE: 20220106
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Saxonov Serge
CENTRAL INDEX KEY: 0001786720
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39035
FILM NUMBER: 22516102
MAIL ADDRESS:
STREET 1: 10X GENOMICS, INC.
STREET 2: 6230 STONERIDGE MALL ROAD
CITY: PLEASANTON
STATE: CA
ZIP: 94588
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: 10x Genomics, Inc.
CENTRAL INDEX KEY: 0001770787
STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826]
IRS NUMBER: 455614458
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 6230 STONERIDGE MALL ROAD
CITY: PLEASANTON
STATE: CA
ZIP: 94588
BUSINESS PHONE: (925) 401-7300
MAIL ADDRESS:
STREET 1: 6230 STONERIDGE MALL ROAD
CITY: PLEASANTON
STATE: CA
ZIP: 94588
FORMER COMPANY:
FORMER CONFORMED NAME: 10X Genomics, Inc.
DATE OF NAME CHANGE: 20190315
4
1
doc1.xml
FORM 4
X0306
4
2022-01-04
0
0001770787
10x Genomics, Inc.
TXG
0001786720
Saxonov Serge
C/O 10X GENOMICS, INC.
6230 STONERIDGE MALL ROAD
PLEASANTON
CA
94588
1
1
0
0
Chief Executive Officer
Class A Common Stock
2022-01-04
4
M
0
3037
11.48
A
937255
D
Class A Common Stock
2022-01-04
4
S
0
1000
138.8636
D
936255
D
Class A Common Stock
2022-01-04
4
S
0
3100
139.8207
D
933155
D
Class A Common Stock
2022-01-04
4
S
0
5368
140.9580
D
927787
D
Class A Common Stock
2022-01-04
4
S
0
2932
141.7179
D
924855
D
Class A Common Stock
2022-01-04
4
S
0
700
143.1125
D
924155
D
Class A Common Stock
2022-01-04
4
S
0
1400
144.7818
D
922755
D
Class A Common Stock
2022-01-04
4
S
0
500
145.3260
D
922255
D
Class A Common Stock
4138
I
See footnote
Class A Common Stock
89960
I
See footnote
Stock Option (right to buy)
11.48
2022-01-04
4
M
0
3037
0.00
D
2029-05-10
Class A Common Stock
3037
45559
D
The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
This transaction was executed in multiple trades at prices ranging from $138.29 to $139.28. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
This transaction was executed in multiple trades at prices ranging from $139.33 to $140.29. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
This transaction was executed in multiple trades at prices ranging from $140.38 to $141.375. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
This transaction was executed in multiple trades at prices ranging from $141.38 to $142.17. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
This transaction was executed in multiple trades at prices ranging from $142.99 to $143.39. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
This transaction was executed in multiple trades at prices ranging from $144.185 to $145.15. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
This transaction was executed in multiple trades at prices ranging from $145.19 to $145.71. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee.
The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee.
This option, originally for 145,786 shares, of which 100,227 have been exercised, vested as to 1/48th of the shares on May 1, 2019, and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.
/s/ Eric S. Whitaker, as Attorney-in-Fact
2022-01-06